Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine pre-treatment in seasonal allergic rhinitis
NCT05692154Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexofenadine in seasonal allergic rhinitis (SAR), sponsored by Sanofi. Started Jan 2023; status: completed.
02
Drugs
fexofenadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05692154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05692154.